Karo Bio Stock Plunges, Safety Issues Scuttle Eprotirome Trial
Shares in Karo Bio AB plunged more than 66 percent Tuesday on news that the company was terminating a Phase III pivotal trial of its lead drug eprotirome, after a toxicology study in dogs indicated that long-term exposure could result in cartilage damage.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter